SARS-CoV-2感染的皮肤表现:临床更新
该综述检索截至2020年5月20日的英文文献,汇总SARS-CoV-2感染的皮肤表现。相关皮损可分为四类:发疹型、血管型、荨麻疹型及肢端丘疹型,另需考虑治疗药物引起的皮肤不良反应。SARS-CoV-2是否直接加重银屑病或特应性皮炎等慢性炎症性疾病尚待确定。
要点
- SARS-CoV-2感染相关皮损可分为发疹型、血管型、荨麻疹型和肢端丘疹型四类。
- 需注意COVID-19治疗药物引起的皮肤不良反应。
- SARS-CoV-2是否直接加重银屑病或特应性皮炎尚不明确。
核心结论
- SARS-CoV-2感染的皮肤表现可分为发疹型、血管型、荨麻疹型和肢端丘疹型四类,另需考虑治疗药物引起的皮肤不良反应。
- SARS-CoV-2感染是否直接加重银屑病或特应性皮炎等慢性炎症性疾病尚待确定。
研究设计与样本
- 综述,检索截至2020年5月20日的英文文献,纳入报告SARS-CoV-2感染皮肤表现的原发病例或病例系列。
- 检索数据库包括PubMed、Embase、Google Scholar和ResearchGate。
主要发现
- 发疹型包括水痘样、丘疹水疱型和麻疹样皮疹。
- 血管型包括冻疮样、紫癜/瘀点样和青斑样皮损。
- 其他类型包括荨麻疹型和肢端丘疹型。
- 其他需考虑的皮肤表现为COVID-19治疗药物引起的皮肤不良反应。
临床怎么用
- 临床遇到发疹型、血管型、荨麻疹型或肢端丘疹型皮损时,应将SARS-CoV-2感染纳入鉴别诊断。
- 对COVID-19患者出现皮肤表现时,需评估治疗药物引起的皮肤不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On 11 March 2020, the World Health Organization (WHO) has declared the novel coronavirus disease (COVID-19) a global pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus). A consistent number of case reports and clinical series have been already published describing a complex spectrum of skin manifestations associated with the SARS-CoV-2 infection. We carried out a review of the English-language literature up to 20 May 2020, reporting original cases or case series of the cutaneous manifestations of SARS-CoV-2 virus infection. The following databases were consulted: PubMed, Embase, Google Scholar and ResearchGate. The search of papers was conducted by using the key term 'COVID-19' or 'SARS-CoV-2' or 'coronavirus' combined with each of the following: 'skin', 'cutaneous', 'dermatologic' or 'dermatology', 'manifestation', 'lesions', or 'rash'. The patterns of dermatological manifestations associated with SARS-CoV-2 infection could be classified into four categories: exanthema (varicella-like, papulo-vesicular and morbilliform rash), vascular (chilblain-like, purpuric/petechial and livedoid lesions), urticarial and acro-papular eruption. Lastly, other skin manifestations to be considered are the cutaneous adverse reactions to the drugs prescribed for the treatment of COVID-19. Whether SARS-CoV-2 infection can directly cause a worsening of chronic inflammatory diseases such as psoriasis or atopic dermatitis remains to be determined. Dermatology's outlook in the COVID-19 pandemic is multidimensional.
引用
- Gisondi P, PIaserico S, Bordin C, et al. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020. PMID: 32585074. doi:10.1111/jdv.16774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。